TLDR
- Scilex stock drops as revenue misses and losses widen sharply
- SCLX slides after earnings miss and steep 67% revenue decline
- Annual loss hits $374M as Scilex faces rising cost pressure
- Weak sales and higher expenses push Scilex deeper into losses
- SCLX dips as quarterly results fall far below expectations
Scilex Holding Co (SCLX) stock declined sharply after weak quarterly results and a steep revenue drop. The stock fell to $6.80, down 3.00%, after early strength faded into sustained selling pressure. Consequently, the session ended with a sharp late decline near the $6.40 level.
Earnings Miss and Revenue Decline Pressure Performance
Scilex reported a quarterly adjusted loss of $2.21 per share, missing analyst expectations significantly. Analysts had projected a smaller loss of $0.47 per share for the same period. Therefore, the earnings gap reflected weaker operational performance and higher cost pressures.
Revenue also dropped sharply during the quarter, falling 67.8% to $4.79 million year-over-year. Analysts had expected revenue of $12.10 million, indicating a substantial shortfall. As a result, the company’s financial results reflected declining product demand and weaker sales execution.
The company also reported a GAAP loss of $4.60 per share and a quarterly net loss of $33.11 million. These figures showed a deeper deterioration compared to prior periods. Hence, the results signaled continued financial strain despite prior expectations of gradual improvement.
Annual Loss Widens as Costs and Impairments Increase
Scilex reported full-year 2025 net revenue of $30.3 million, down from $56.6 million in 2024. The decline resulted mainly from lower sales of key products such as ZTlido and ELYXYB. Consequently, reduced product traction weighed heavily on overall revenue performance.
The company posted a consolidated net loss of $374.1 million for the year. This loss included a $73.4 million goodwill impairment and losses tied to digital assets. Therefore, non-operational factors significantly amplified the overall financial decline.
Operating loss widened to $346.0 million due to higher selling, general, and administrative expenses. Transaction-related costs also contributed to the increased losses during the year. As a result, cost expansion outpaced revenue generation, intensifying financial pressure.
Product Pipeline and Strategy Show Mixed Progress
Scilex continued advancing its product pipeline despite financial setbacks. The company completed a Phase 3 trial for SEMDEXA and initiated a second Phase 3 study. It reported positive Phase 2 results for SP-103 and completed Phase 1 for SP-104.
The company expanded its commercial strategy by increasing direct distribution to wholesalers. It also maintained a third-party sales force for ZTlido to support market reach. Therefore, management aimed to stabilize revenue through broader distribution channels.
New product launches included GLOPERBA in June 2024 and ELYXYB expansion into Canada in early 2025. These moves targeted growth within the non-opioid pain treatment segment. Declining revenue trends indicated that recent launches have not yet offset broader sales weakness.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
